Interestingly, over 30% of high-grade serous ovarian tumors are associated with PTEN loss[77], which subsequently triggers the activation of the PI3-K/protein kinase B (AKT) pathway, leading to uncontrolled cell cycle progression, diminished apoptosis, and increased metastatic disease in ovarian cancer[78]. Here, AKT1 is linked to metastatic neoplasm.